Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hypertension
Biotech
Retension, Lilly-backed TRex both plan to join IPO stampede
Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals are the latest biotechs to set out plans to go public this year.
James Waldron
Sep 21, 2026 4:29am
In deal fraud dispute with Novo, KBP looks to revive heart drug
Apr 1, 2026 2:30am
Kardigan hypertension drug tangles biomarker win with BP miss
Mar 30, 2026 5:11am
Cardiac tech pushes Medtronic's Q2 earnings past expectations
Nov 18, 2025 11:15am
Novo Nordisk vs. KBP: From $1.3B deal to legal battlefield
Oct 2, 2025 3:00am
FDA warns against unreviewed blood pressure tech, baby monitors
Sep 17, 2025 12:00pm
